|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Telmisartan#Pharmacology]] |
| {{Telmisartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Description==
| |
| | |
| MICARDIS is a non-peptide angiotensin II receptor (type AT1) antagonist.
| |
| Telmisartan is chemically described as 4'-[(1,4'-dimethyl-2'-propyl [2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid. Its empirical formula is C33H30N4O2, its molecular weight is 514.63, and its structural formula is:
| |
| | |
| {|
| |
| | |
| |[[File:TELMISARTAN02.jpg|thumb|800px]]
| |
| | |
| |}
| |
| | |
| Telmisartan is a white to slightly yellowish solid. It is practically insoluble in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except insoluble in hydrochloric acid), and soluble in strong base. | |
| | |
| MICARDIS is available as tablets for oral administration, containing 20 mg, 40 mg or 80 mg of telmisartan. The tablets contain the following inactive ingredients: sodium hydroxide, meglumine, povidone, sorbitol, and magnesium stearate. MICARDIS tablets are hygroscopic and require protection from moisture.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MICARDIS (TELMISARTAN) TABLET [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cfb9309f-e0df-4a55-9542-0e869fce05fb | publisher = | date = | accessdate = 24 February 2014 }}</ref></div>
| |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Benzimidazoles]]
| |
| [[Category:Benzoic acids]]
| |
| [[Category:Biphenyls]]
| |
| [[Category:PPAR agonists]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |